

RAI1 Gene Analysis in Smith-Magenis Syndrome

Clinical Features:

Smith-Magenis Syndrome (SMS) is characterized by facial dysmorphism, behavioral problems, sleep disturbances, growth retardation and moderate intellectual disability. The classic facial features tend to progress with age and include brachycephaly, mid-facial hypoplasia with broad flat midface, broad nasal bridge, and prognathism. Cognitive, psychomotor, and speech delays are common. Neurobehavioral features become more pronounced with age and can include hyperactivity, temper tantrums, attention-seeking, self-hugging, self-injurious behaviors, and sleep disturbances. A recent study of 26 patients with confirmed 17p11.2 deletions found that 90% met diagnostic criteria for autism spectrum disorders.¹ About 40% of patients with the 17p11.2 deletion have structural or functional congenital heart defects. Hoarse voice, hearing loss, and eye abnormalities are frequently present as well. Hypercholesterolemia has been reported in 70% of affected patients².

Genetics:

Autosomal dominant. Most cases are sporadic, but parental mosaicism and rare heritable chromosome rearrangements that lead to loss of 17p11.2 have been reported; therefore, parental testing is recommended.³

Test Methods:

Most cases (90%) of SMS are due to an interstitial deletion of the 17p11.2 critical region that includes the entire *RAI1* gene (and other genes). Of those patients with deletions, 70% carry a recurrent 3.7-Mb deletion.³ GeneDx offers whole genome oligonucleotide microarray analysis (GenomeDx), which can detect the common 17p11.2 deletion as well as other microdeletion/microduplication syndromes with clinical features overlapping with Smith Magenis.³ Alternatively, FISH analysis with the *RAI1* gene probe is also available to detect the common 17p11.2 deletion.⁴ For those SMS cases in which the classic 3.7-Mb deletion is not identified, GeneDx performs bi-directional sequence analysis of exon 3 of the *RAI1* gene and its flanking intron sequences. Concurrently, targeted array CGH analysis with exon-level resolution (ExonArrayDx) is performed to evaluate for a deletion or duplication of individual exons within the *RAI1* gene. Exon 3 represents approximately 95% of the coding sequence of this gene and is where all *RAI1* variants have been reported to date. Variants found in the first person of a family to be tested are confirmed by repeat analysis using sequencing, restriction fragment analysis, or another appropriate method.

Test Sensitivity:

The FISH test for SMS deletion is positive in 90% of cases. Studies of 17p11.2 deletion-negative SMS patients have described a total of 14 different *RAI1* variants identified by

sequence analysis.^{6,7} pathogenic variants in exon 3 of the RAI1 gene are identified in approximately 10-11% of individuals with Smith Magenis syndrome who have had a negative FISH test.^{3, 6}

References:

1. Laje et al. (2010) Autism Spectrum Features in Smith-Magenis Syndrome. *Am J Med Genet C Semin Med Genet* 154C(4): 456-462.
2. Nakamine et al. (2008) Duplication of 17(p11.2p11.2) in a male child with autism and severe language delay. *Am J Med Genet.* 146A(5):636-643.
3. Elsea et al. (2008) Smith-Magenis Syndrome. *European Journal of Human Genetics* 16: 412-421. doi: 10.1038/sj.ejhg.5202009.
4. Bi et al. (2004) Mutations of RAI1, a PHD-containing protein, in non-deletion patients with Smith-Magenis syndrome. *Hum Genet.* 115: 515-24.
5. Girirajan et al., RAI1 variations in Smith-Magenis syndrome patients without 17p11.2 deletions. *J Med Genet.* 42: 820-28, 2005.
6. Vilboux et al. (2011) Molecular Analysis of the Retinoic Acid Induced 1 Gene (RAI1) in Patients with Suspected Smith-Magenis Syndrome without the 17p11.2 Deletion. *PLoS ONE* 6(8): E22861. doi:10.1371.
7. Truong et al., (2010) Frameshift mutation hotspot identified in Smith-Magenis syndrome: case report and review of literature. *BMC Medical Genetics* 11:142.
8. Slager et al. (2003) Mutations in RAI1 associated with Smith-Magenis syndrome. *Nat Genet.* 33: 466-68.
9. Potocki et al. (2007) Characterization of Potocki-Lupski syndrome (dup(17)(p11.2p11.2)) and delineation of a dosage-sensitive critical interval that can convey an autism phenotype. *Am J Hum Genet* 80:633-649.